Published in Sci Rep on September 22, 2017
Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods (2008) 126.81
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol (2014) 27.48
MicroRNA genes are transcribed by RNA polymerase II. EMBO J (2004) 20.65
Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest (2003) 13.72
VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med (2008) 9.87
A large-scale analysis of mRNA polyadenylation of human and mouse genes. Nucleic Acids Res (2005) 7.24
RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol (2006) 6.81
Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest (2003) 6.44
Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol (2013) 6.24
GENECODIS: a web-based tool for finding significant concurrent annotations in gene lists. Genome Biol (2007) 6.11
Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ (2005) 5.96
VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol (2005) 5.56
Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A (1993) 5.02
Corneal avascularity is due to soluble VEGF receptor-1. Nature (2006) 4.77
Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nat Med (2008) 3.98
GeneCodis: interpreting gene lists through enrichment analysis and integration of diverse biological information. Nucleic Acids Res (2009) 3.91
A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med (2008) 3.39
GeneCodis3: a non-redundant and modular enrichment analysis tool for functional genomics. Nucleic Acids Res (2012) 3.29
Complex and dynamic landscape of RNA polyadenylation revealed by PAS-Seq. RNA (2011) 2.91
A quantitative atlas of polyadenylation in five mammals. Genome Res (2012) 2.87
Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology (2004) 2.83
Distinct subsets of microRNAs are expressed differentially in the human placentas of patients with preeclampsia. Am J Obstet Gynecol (2007) 2.78
Pathogenesis of preeclampsia. Annu Rev Pathol (2010) 2.66
Subclassification of preeclampsia. Hypertens Pregnancy (2003) 2.25
Molecular evidence of placental hypoxia in preeclampsia. J Clin Endocrinol Metab (2005) 1.98
Bias detection and correction in RNA-Sequencing data. BMC Bioinformatics (2011) 1.93
Risk factors for preeclampsia in healthy nulliparous women: a prospective multicenter study. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Am J Obstet Gynecol (1995) 1.92
An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol (2009) 1.92
Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation (2012) 1.88
Transcriptionally active syncytial aggregates in the maternal circulation may contribute to circulating soluble fms-like tyrosine kinase 1 in preeclampsia. Hypertension (2012) 1.86
Differential placental gene expression in severe preeclampsia. Placenta (2009) 1.85
A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med (2009) 1.84
Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol (2004) 1.81
Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1. Am J Physiol Regul Integr Comp Physiol (2006) 1.81
Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation (2010) 1.74
Angiogenic factors and preeclampsia. Semin Nephrol (2011) 1.58
Pre-eclampsia rates in the United States, 1980-2010: age-period-cohort analysis. BMJ (2013) 1.56
The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol (2011) 1.50
Epidemiology and Mechanisms of De Novo and Persistent Hypertension in the Postpartum Period. Circulation (2015) 1.46
MiR-214 targets β-catenin pathway to suppress invasion, stem-like traits and recurrence of human hepatocellular carcinoma. PLoS One (2012) 1.42
Differential placental gene expression in preeclampsia. Am J Obstet Gynecol (2008) 1.38
An efficient method for genome-wide polyadenylation site mapping and RNA quantification. Nucleic Acids Res (2013) 1.30
Role of RIP140 in metabolic tissues: connections to disease. FEBS Lett (2007) 1.29
Induction of antagonistic soluble decoy receptor tyrosine kinases by intronic polyA activation. Mol Cell (2011) 1.28
Intronic polyadenylation signal sequences and alternate splicing generate human soluble Flt1 variants and regulate the abundance of soluble Flt1 in the placenta. FASEB J (2007) 1.22
Selective overexpression of the hypoxia-inducible transcription factor, HIF-2alpha, in placentas from women with preeclampsia. Biol Reprod (2001) 1.19
A recently evolved novel trophoblast-enriched secreted form of fms-like tyrosine kinase-1 variant is up-regulated in hypoxia and preeclampsia. J Clin Endocrinol Metab (2009) 1.16
Novel splice variants of sFlt1 are upregulated in preeclampsia. Placenta (2009) 1.14
A single-nucleotide polymorphism in a half-binding site creates p53 and estrogen receptor control of vascular endothelial growth factor receptor 1. Mol Cell Biol (2007) 1.13
Microarray profiling reveals that placental transcriptomes of early-onset HELLP syndrome and preeclampsia are similar. Placenta (2010) 1.11
Human placental trophoblast invasion and differentiation: a particular focus on Wnt signaling. Front Genet (2013) 1.11
Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion. J Matern Fetal Neonatal Med (2011) 1.07
Essential requirement of CCAAT/enhancer binding proteins in embryogenesis. Mol Cell Biol (2004) 1.07
miR-210 targets iron-sulfur cluster scaffold homologue in human trophoblast cell lines: siderosis of interstitial trophoblasts as a novel pathology of preterm preeclampsia and small-for-gestational-age pregnancies. Am J Pathol (2011) 1.06
Hypoxia is responsible for soluble vascular endothelial growth factor receptor-1 (VEGFR-1) but not for soluble endoglin induction in villous trophoblast. Hum Reprod (2008) 1.04
Variations of microRNAs in human placentas and plasma from preeclamptic pregnancy. Hypertension (2014) 1.04
Identification of target genes regulated by PAX3 and PAX3-FKHR in embryogenesis and alveolar rhabdomyosarcoma. Genomics (2002) 1.01
Extensive shift in placental transcriptome profile in preeclampsia and placental origin of adverse pregnancy outcomes. Sci Rep (2015) 0.95
Distinct functions for RIP140 in development, inflammation, and metabolism. Trends Endocrinol Metab (2013) 0.90
Gene expression profiling of placentae from women with early- and late-onset pre-eclampsia: down-regulation of the angiogenesis-related genes ACVRL1 and EGFL7 in early-onset disease. Mol Hum Reprod (2011) 0.87
Expression of placental FLT1 transcript variants relates to both gestational hypertensive disease and fetal growth. Hypertension (2011) 0.87
Preeclampsia leads to dysregulation of various signaling pathways in placenta. J Hypertens (2011) 0.87
Involvement of Flt-1 (VEGF receptor-1) in cancer and preeclampsia. Proc Jpn Acad Ser B Phys Biol Sci (2011) 0.87
Alternate processing of Flt1 transcripts is directed by conserved cis-elements within an intronic region of FLT1 that reciprocally regulates splicing and polyadenylation. Nucleic Acids Res (2010) 0.86
MicroRNAs in placental health and disease. Am J Obstet Gynecol (2015) 0.85
Risk factors and effective management of preeclampsia. Integr Blood Press Control (2015) 0.84
Gene expression profiling of pre-eclamptic placentae by RNA sequencing. Sci Rep (2015) 0.83
The coordinated p53 and estrogen receptor cis-regulation at an FLT1 promoter SNP is specific to genotoxic stress and estrogenic compound. PLoS One (2010) 0.83
Extravillous trophoblast-associated ADAM12 exerts pro-invasive properties, including induction of integrin beta 1-mediated cellular spreading. Biol Reprod (2014) 0.82
Large scale aggregate microarray analysis reveals three distinct molecular subclasses of human preeclampsia. PLoS One (2015) 0.82
An optimized kit-free method for making strand-specific deep sequencing libraries from RNA fragments. Nucleic Acids Res (2014) 0.81
Hypoxia-inducible miR-210 contributes to preeclampsia via targeting thrombospondin type I domain containing 7A. Sci Rep (2016) 0.81
The Rising Burden of Preeclampsia in the United States Impacts Both Maternal and Child Health. Am J Perinatol (2015) 0.80
Differences and similarities in the transcriptional profile of peripheral whole blood in early and late-onset preeclampsia: insights into the molecular basis of the phenotype of preeclampsiaa. J Perinat Med (2013) 0.80
Hypoxia down-regulates sFlt-1 (sVEGFR-1) expression in human microvascular endothelial cells by a mechanism involving mRNA alternative processing. Biochem J (2011) 0.80
Knockdown of long non-coding RNA TP73-AS1 inhibits cell proliferation and induces apoptosis in esophageal squamous cell carcinoma. Oncotarget (2016) 0.79
Feedback Mechanisms Regulate Ets Variant 2 (Etv2) Gene Expression and Hematoendothelial Lineages. J Biol Chem (2015) 0.79
Placenta-derived angiogenic proteins and their contribution to the pathogenesis of preeclampsia. Angiogenesis (2014) 0.78
Full-length human placental sFlt-1-e15a isoform induces distinct maternal phenotypes of preeclampsia in mice. PLoS One (2015) 0.78
Erythropoietin-mediated expression of placenta growth factor is regulated via activation of hypoxia-inducible factor-1α and post-transcriptionally by miR-214 in sickle cell disease. Biochem J (2015) 0.78
ADAM12 and PAPP-A: Candidate regulators of trophoblast invasion and first trimester markers of healthy trophoblasts. Cell Adh Migr (2015) 0.78
Transcriptional coregulator RIP140: an essential regulator of physiology. J Mol Endocrinol (2017) 0.76
Placental-Specific sFLT-1 e15a Protein Is Increased in Preeclampsia, Antagonizes Vascular Endothelial Growth Factor Signaling, and Has Antiangiogenic Activity. Hypertension (2015) 0.76
Epithelial-mesenchymal transition during extravillous trophoblast differentiation. Cell Adh Migr (2016) 0.76
Accurate identification of polyadenylation sites from 3' end deep sequencing using a naive Bayes classifier. Bioinformatics (2013) 0.76
Validation of hospital discharge diagnoses for hypertensive disorders of pregnancy. Acta Obstet Gynecol Scand (2016) 0.76
Regulation of soluble Flt-1 (VEGFR-1) production by hnRNP D and protein arginine methylation. Mol Cell Biochem (2016) 0.76
Angiogenic and Antiangiogenic Markers for Prediction and Risk Classification of Preeclampsia. Clin Obstet Gynecol (2017) 0.76